Applicant: Francis X. Ignatious Attorney's Dock Oc.: 00537-181002 / BPC071

Serial No.: 09/744,350 Filed: January 23, 2001

Page: 6

## REMARKS

Applicant hereby submits that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket no. 00537-181002.

Respectfully submitted,

Date: March 22, 2002

Jeffrey D. Hsi Reg. No. 40,024

Fish & Richardson P.C. 225 Franklin Street Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20403763.doc

Attorney's Dock o.: 00537-181002 / BPC071

Applicant: Francis X. Ignatious

Serial No.: 09/744,350 Filed

: January 23, 2001

Page

## "Version With Markings to Show Changes Made"

## In the specification:

Paragraph beginning at page 9, line 13, has been amended as follows:

Examples of somatostatin analogs include, but are not limited to, the following somatostatin analogs which are disclosed in the above-cited references:

```
H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH<sub>2</sub>;
H-D-β-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH<sub>2</sub>;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH<sub>2</sub>;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;
Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp*-Thr-NH<sub>2</sub> (an amide bridge formed between Lys* and
Asp*);
Ac-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
Ac-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;
```

Applicant: Francis X. Ignatious

Serial No.: 09/744,350 Filed: January 23, 2001

Page: 8

Ac-D-hArg(Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-L-hArg(Et)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;

Ac-L-hArg(CH<sub>2</sub>-CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHEt;

Ac-hArg(CH<sub>3</sub>, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

H-hArg(hexyl<sub>2</sub>)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;

Ac-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>;

Propionyl-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-β-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)<sub>2</sub>-NH<sub>2</sub>;

Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-D-hArg(CH<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH<sub>2</sub>;

Ac-D-hArg(Et)<sub>2</sub>-D-hArg(Et)<sub>2</sub>-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>;

Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH<sub>2</sub>;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH<sub>2</sub>;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH<sub>2</sub>;

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>;

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH<sub>2</sub>;

H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

Ac-D-β-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>;

H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>;

Applicant: Francis X. Ignatious

Serial No.: 09/744,350 Filed: January 23, 2001

Page : 9

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH<sub>2</sub>; H-D-β-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>; H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>; Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH<sub>2</sub>; H-D-Phe-Cys-β-Nal-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>; H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH<sub>2</sub>; cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe); cyclo(Pro-Tyr-D-Trp-Lys-Thr-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe); cyclo(Pro-Phe-L-Trp-Lys-Thr-Phe) (SEQ ID NO:1); cyclo(Pro-Phe-D-Trp(F)-Lys-Thr-Phe); cyclo(Pro-Phe-Trp(F)-Lys-Thr-Phe) (SEQ ID NO:2); cyclo(Pro-Phe-D-Trp-Lys-Ser-Phe); cyclo(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe); cyclo(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe); cyclo(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr); cyclo(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe); cyclo(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe); cyclo(Pro-Phe-D-Trp-4-Amphe-Thr-Phe); cyclo(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe); cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba); cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba);

Applicant: Francis X. Ignatious

Serial No.: 09/744,350 Filed: January 23, 2001

Page: 10

```
cyclo(Asn-Phe-D-Trp-Lys-Thr-Phe);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH<sub>2</sub>)<sub>4</sub>CO);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-β-Ala);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH;
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly);
cyclo(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba);
cyclo(Asn-Phe-Phe-D-Trp(NO<sub>2</sub>)-Lys-Thr-Phe-Gaba);
cyclo(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) (SEQ ID NO:3);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba);
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH;
cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH;
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba);
cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba);
cyclo(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba);
cyclo(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH<sub>2</sub>)<sub>3</sub>-CO);
cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
cyclo(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>;
H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub>;
H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>; and
H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>.
```